

AlxB: Revolutionizing Biotech with Artificial Intelligence

Crossbreed for complete conquering and complete control

Company Overview

AlxB is a cutting-edge startup at the intersection of AI and Biotech. We are dedicated to developing minimal genome organisms and leveraging AI algorithms for genetic analysis and editing. Our goal is to revolutionize the biotech industry by enabling cost-effective drug production and personalized healthcare solutions.

Problem

The current drug production process is costly, time-consuming, and inaccessible to many. There is a lack of efficient genetic analysis and editing tools for personalized healthcare advancements.

Solution

AlxB addresses these challenges by:

1. Developing minimal genome organisms for streamlined drug production, resulting in reduced costs and faster time-to-market.
2. Utilizing AI algorithms for advanced genetic analysis enables the identification of disease markers, drug targets, and personalized treatment options.
3. Leveraging AI-based genome editing to achieve precise modifications in organisms for enhanced traits.

Market Opportunity

The biotech market is projected to reach \$727.1 billion by 2025, while AI in the healthcare market is expected to reach \$66.8 billion by the same year.

Competitive Advantage

AlxB stands out with:

1. A unique blend of AI and Biotech expertise.
2. A strong focus on cost-effective drug production.
3. State-of-the-art AI algorithms for genetic analysis and editing.
4. Collaborative partnerships for industry adoption.

Business Model

Revenue streams:

1. Sale of minimal genome organisms for drug production.
2. Licensing AI-based genetic analysis and editing tools.
3. Partnerships with pharmaceutical and biotech companies.
4. Target customers: Pharmaceutical companies, biotech startups, research institutions, and healthcare providers.

Milestones

R&D Phase: Developing and testing minimal genome organisms.

AI Algorithm Development: Enhancing genetic analysis and editing tools.

Strategic Partnerships: Collaborating with industry leaders for validation and adoption.

Market Launch: Commercializing minimal genome organisms and AI-based solutions.

Funding Requirements

Seeking ₹100Cr funding to:

1. Expand R&D capabilities
2. Scale AI algorithm development
3. Build strategic partnerships
4. Launch and market minimal genome organisms

Contact Information

Ratnesh Kumar Sharma

Founder, AlxB

BTech, Biochemical Engineering and Biotechnology,
IIT Delhi.

Email: rksiitd123@gmail.com or bb1190047@iitd.ac.in or i@rksiitd.io

Phone: +91 97085 81960

<https://rksiitd.io/>

<https://www.facebook.com/rksiitd>

<https://www.instagram.com/rksiitd/>

<https://twitter.com/rksiitd>

<https://www.youtube.com/@rksiitd/>

<https://www.linkedin.com/in/rksiitd/>

Closing Statement

AlxB is poised to disrupt the biotech industry with our groundbreaking approach. Join us in our mission to transform drug production and healthcare through the power of AI and Biotech.
